DSS 📈 DSS - Overview
Exchange: NYSE MKT • Country: United States • Currency: USD • Type: Common Stock • ISIN: US26253C1027
DSS: Packaging, Biotech, Finance, Securities, Lending, Healthcare
DSS, Inc. operates in the product packaging, biotechnology, commercial lending, securities and investment management, alternative trading, and direct marketing businesses. It manufactures, markets, and sells mailers, photo sleeves, custom folding cartons, and 3-dimensional direct mail solutions; and markets and distributes nutritional and personal care products. The company also invests in or acquires companies in the biohealth and biomedical fields, including businesses that focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases; and develops open-air defense initiatives for air-borne infectious diseases comprising tuberculosis and influenza. In addition, it focuses on acquiring equity positions in undervalued commercial banks, bank holding companies, and nonbanking licensed financial companies; and companies engages in nonbanking activities related to banking, such as loan syndication, mortgage banking, trust and escrow, banking technology, loan servicing, equipment leasing, problem asset management, special purpose acquisition company consulting, and advisory capital raising services. Further, the company provides securities and investment management services; and operates a real estate investment trust for acquiring hospitals and other acute or post-acute care centers. Additionally, it develops and/or acquires assets and investments in the securities trading and/or funds management arena, as well as operates as a digital assets broker dealer. The company was formerly known as Document Security Systems, Inc. and changed its name to DSS, Inc. in September 2021. DSS, Inc. was incorporated in 1984 and is headquartered in West Henrietta, New York. Web URL: https://www.dssworld.com
Additional Sources for DSS Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
DSS Stock Overview
Market Cap in USD | 6m |
Sector | Consumer Cyclical |
Industry | Packaging & Containers |
GiC Sub-Industry | Commercial Printing |
IPO / Inception | 1997-01-03 |
DSS Stock Ratings
Growth 5y | -98.8% |
Fundamental | -52.4% |
Dividend | - |
Rel. Strength Industry | -417 |
Analysts | 5/5 |
Fair Price Momentum | 0.28 USD |
Fair Price DCF | - |
DSS Dividends
No Dividends PaidDSS Growth Ratios
Growth Correlation 3m | -76.1% |
Growth Correlation 12m | -94.8% |
Growth Correlation 5y | -98.4% |
CAGR 5y | -65.11% |
CAGR/Mean DD 5y | -0.80 |
Sharpe Ratio 12m | -1.47 |
Alpha | -75.89 |
Beta | 0.16 |
Volatility | 83.46% |
Current Volume | 74.6k |
Average Volume 20d | 68.4k |
What is the price of DSS stocks?
As of December 22, 2024, the stock is trading at USD 0.83 with a total of 74,602 shares traded.
Over the past week, the price has changed by -19.60%, over one month by -20.38%, over three months by -33.22% and over the past year by -67.42%.
As of December 22, 2024, the stock is trading at USD 0.83 with a total of 74,602 shares traded.
Over the past week, the price has changed by -19.60%, over one month by -20.38%, over three months by -33.22% and over the past year by -67.42%.
Is DSS a good stock to buy?
No, based on ValueRay Fundamental Analyses, DSS (NYSE MKT:DSS) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -52.38 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DSS as of December 2024 is 0.28. This means that DSS is currently overvalued and has a potential downside of -66.27%.
No, based on ValueRay Fundamental Analyses, DSS (NYSE MKT:DSS) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -52.38 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DSS as of December 2024 is 0.28. This means that DSS is currently overvalued and has a potential downside of -66.27%.
Is DSS a buy, sell or hold?
DSS has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy DSS.
DSS has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy DSS.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for DSS stock price target?
According to ValueRays Forecast Model, DSS DSS will be worth about 0.3 in December 2025. The stock is currently trading at 0.83. This means that the stock has a potential downside of -63.86%.
According to ValueRays Forecast Model, DSS DSS will be worth about 0.3 in December 2025. The stock is currently trading at 0.83. This means that the stock has a potential downside of -63.86%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 27.6 | 3225.3% |
Analysts Target Price | 1.5 | 80.7% |
ValueRay Target Price | 0.3 | -63.9% |